• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Orchestra BioMed to Showcase Transformative Potential of AVIM Therapy in Keynote Presentation on Hypertensive Heart Disease at Georgia Innovation Summit

    10/9/25 8:00:00 AM ET
    $MDT
    $OBIO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $MDT alert in real time by email
    • Presentation to provide comprehensive overview of AVIM Therapy clinical evidence demonstrating the potential to halt the progression of hypertensive heart disease
    • Orchestra BioMed and Medtronic (NYSE:MDT) have a strategic collaboration to develop and commercialize AVIM Therapy for the treatment of uncontrolled hypertension in patients indicated for a pacemaker, an estimated global population of over 750,000 patients annually
    • AVIM Therapy has received FDA Breakthrough Device Designation for the treatment of uncontrolled hypertension in patients with increased cardiovascular risk, an estimated U.S. population of over 7.7 million patients



    NEW HOPE, Pa., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company")), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, today announced a data summary supporting the transformative potential of Atrioventricular Interval Modulation ("AVIM") Therapy in the management of hypertensive heart disease will be presented in a keynote talk at the Georgia Innovation Summit in Tbilisi, Georgia on October 10, 2025. The presentation, to be delivered by Avi Fischer, MD, Senior Vice President of Medical Affairs and Innovation at Orchestra BioMed, will showcase AVIM Therapy as a novel, device-based therapeutic approach targeting hypertensive heart disease progression and its potential to redefine standards of care.

    Dr. Fischer commented, "This keynote presentation reflects the growing global recognition of AVIM Therapy as a novel, device-based therapy, poised to reshape the future of hypertension care. Hypertension is the principal driver of diastolic dysfunction, which accelerates the development of heart failure. Despite widespread use of antihypertensive therapies, many patients continue to progress along the disease pathway, underscoring the importance of novel therapeutic approaches. The collective body of AVIM Therapy clinical data demonstrates its potential to directly modulate the progression of hypertensive heart disease, offering the potential to intervene earlier in the course of the disease to improve long-term outcomes, transform patient care, and ultimately create lasting value for all stakeholders."

    The keynote presentation will provide a comprehensive overview of clinical and mechanistic AVIM Therapy results from pilot and long-term follow-up studies, highlighting the therapy's consistent favorable clinical impact on blood pressure and cardiac function:

    • Immediate, substantial, and sustained blood pressure reduction
      • MODERATO I pilot study: 24-hour ambulatory systolic blood pressure ("aSBP") reduced by 11.6 mmHg at 1 day and 10.1 mmHg at 3 months
      • MODERATO II pilot study: 24-hour aSBP reduced by 15.6 mmHg at 1 day and 11.1 mmHg at 6 months, as well as an office systolic blood pressure reduction of 17.5 mmHg at 24 months
    • Favorable impact on cardiac hemodynamics after 24 months of treatment (MODERATO I)
      • Significant reductions in heart rate and end-diastolic volume
      • No significant changes in end-systolic volume or ejection fraction, supporting safety
    • Improvement in echocardiographic measures of diastolic function (MODERATO II)
      • Significant increases in e' and E/A ratio, indicating improved myocardial relaxation and diastolic compliance
    • Potential to halt hypertensive heart disease progression
      • Long-term follow-up demonstrates sustained blood pressure reduction with reversibility of effect and absence of rebound hypertension upon deactivation
      • Favorable effects were reproducible after a 7-day washout period followed by reactivation, underscoring durability and reliability



    About Orchestra BioMed

    Orchestra BioMed (NASDAQ:OBIO) is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships with leading medical device companies. Orchestra BioMed's partnership-enabled business model focuses on forging strategic collaborations with leading medical device companies to drive successful global commercialization of products it develops. Orchestra BioMed's lead product candidate is atrioventricular interval modulation (AVIM) therapy (also known as BackBeat Cardiac Neuromodulation Therapy (CNT™)) for the treatment of hypertension, the leading risk factor for death worldwide. Orchestra BioMed is also developing the Virtue® Sirolimus AngioInfusion™ Balloon (SAB) for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. Orchestra BioMed has a strategic collaboration with Medtronic, one of the largest medical device companies in the world, for development and commercialization of AVIM Therapy for the treatment of hypertension in pacemaker-indicated patients, and a strategic partnership with Terumo, a global leader in medical technology, for development and commercialization of Virtue SAB for the treatment of artery disease. For further information about Orchestra BioMed, please visit www.orchestrabiomed.com, and follow us on LinkedIn.

    References to Websites and Social Media Platforms

    References to information included on, or accessible through, websites and social media platforms do not constitute incorporation by reference of the information contained at or available through such websites or social media platforms, and you should not consider such information to be part of this press release.

    About AVIM Therapy

    AVIM Therapy is an investigational therapy compatible with standard dual-chamber pacemakers designed to substantially and persistently lower blood pressure. It has been evaluated in pilot studies in patients with hypertension who are also indicated for a pacemaker. MODERATO II, a double-blind, randomized pilot study, showed that patients treated with AVIM Therapy experienced net reductions of 8.1 mmHg in 24-hour ambulatory systolic blood pressure (aSBP) and 12.3 mmHg in office systolic blood pressure (oSBP) at six months when compared to control patients. In addition to reducing blood pressure, clinical results using AVIM Therapy demonstrate improvements in cardiac function and hemodynamics. The BACKBEAT (BradycArdia paCemaKer with atrioventricular interval modulation for Blood prEssure treAtmenT) global pivotal study will evaluate the safety and efficacy of AVIM Therapy in lowering blood pressure in patients who have systolic blood pressure above target despite anti-hypertensive medication and who are indicated for or have recently received a dual-chamber cardiac pacemaker. AVIM Therapy has been granted Breakthrough Device Designation by the FDA for the treatment of uncontrolled hypertension in patients who have increased cardiovascular risk.

    Forward-Looking Statements

    Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "predict," "potential," "seem," "seek," "future," "outlook" and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements relating to the implementation and design of the BACKBEAT pivotal study, the potential efficacy and safety of the Company's commercial product candidates, the ability of the Company's partnerships to accelerate clinical development, and the Company's late-stage development programs and strategic partnerships. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the Company's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on as a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and may differ from assumptions. Many actual events and circumstances are beyond the control of the Company. These forward-looking statements are subject to a number of risks and uncertainties, including changes in domestic and foreign business, market, financial, political, and legal conditions; risks related to regulatory approval of the Company's product candidates and ongoing regulation of the Company's product candidates, if approved; the timing of, and the Company's ability to achieve, expected regulatory and business milestones; the impact of competitive products and product candidates; and the risk factors discussed under the heading "Item 1A. Risk Factors" in the Company's annual report on Form 10-K for the year ended December 31, 2024, which was filed with the Securities and Exchange Commission on March 31, 2025, as updated by any risk factors disclosed under the heading "Item 1A. Risk Factors" in the Company's subsequently filed quarterly reports on Form 10-Q.

    The Company operates in a very competitive and rapidly changing environment. New risks emerge from time to time. Given these risks and uncertainties, the Company cautions against placing undue reliance on these forward-looking statements, which only speak as of the date of this press release. The Company does not plan and undertakes no obligation to update any of the forward-looking statements made herein, except as required by law.

    Investor Contact

    Silas Newcomb

    Orchestra BioMed

    [email protected]

    Media Contact

    Kelsey Kirk-Ellis

    Orchestra BioMed

    [email protected]



    Primary Logo

    Get the next $MDT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MDT
    $OBIO

    CompanyDatePrice TargetRatingAnalyst
    Orchestra BioMed Holdings Inc.
    $OBIO
    8/20/2025Buy → Neutral
    BTIG Research
    Medtronic plc.
    $MDT
    6/30/2025Underperform → Peer Perform
    Wolfe Research
    Medtronic plc.
    $MDT
    6/16/2025$110.00Outperform
    Leerink Partners
    Orchestra BioMed Holdings Inc.
    $OBIO
    3/20/2025$12.00Buy
    BTIG Research
    Medtronic plc.
    $MDT
    3/4/2025$92.00 → $107.00Neutral → Buy
    Citigroup
    Orchestra BioMed Holdings Inc.
    $OBIO
    1/2/2025$16.00Overweight
    Barclays
    Medtronic plc.
    $MDT
    10/10/2024$98.00 → $105.00Sector Perform → Outperform
    RBC Capital Mkts
    Orchestra BioMed Holdings Inc.
    $OBIO
    8/22/2024$14.00Buy
    H.C. Wainwright
    More analyst ratings

    $MDT
    $OBIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Aryeh Jason bought $2,450 worth of shares (1,000 units at $2.45), increasing direct ownership by 0.93% to 108,482 units (SEC Form 4)

    4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

    9/19/25 6:57:57 PM ET
    $OBIO
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Fain Eric S bought $15,034 worth of shares (5,760 units at $2.61) (SEC Form 4)

    4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

    8/25/25 7:04:50 PM ET
    $OBIO
    Medicinal Chemicals and Botanical Products
    Health Care

    Officer Sherman Darren bought $7,860 worth of shares (3,000 units at $2.62), increasing direct ownership by 0.32% to 926,837 units (SEC Form 4)

    4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

    8/25/25 7:04:17 PM ET
    $OBIO
    Medicinal Chemicals and Botanical Products
    Health Care

    $MDT
    $OBIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Orchestra BioMed downgraded by BTIG Research

    BTIG Research downgraded Orchestra BioMed from Buy to Neutral

    8/20/25 8:28:57 AM ET
    $OBIO
    Medicinal Chemicals and Botanical Products
    Health Care

    Medtronic upgraded by Wolfe Research

    Wolfe Research upgraded Medtronic from Underperform to Peer Perform

    6/30/25 7:56:30 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Leerink Partners initiated coverage on Medtronic with a new price target

    Leerink Partners initiated coverage of Medtronic with a rating of Outperform and set a new price target of $110.00

    6/16/25 7:51:25 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MDT
    $OBIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Aryeh Jason bought $2,450 worth of shares (1,000 units at $2.45), increasing direct ownership by 0.93% to 108,482 units (SEC Form 4)

    4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

    9/19/25 6:57:57 PM ET
    $OBIO
    Medicinal Chemicals and Botanical Products
    Health Care

    Principal Accounting Officer Aiello Joshua covered exercise/tax liability with 203 shares, decreasing direct ownership by 1% to 19,126 units (SEC Form 4)

    4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

    9/19/25 5:31:31 PM ET
    $OBIO
    Medicinal Chemicals and Botanical Products
    Health Care

    Chief Financial Officer Taylor Andrew Lawrence covered exercise/tax liability with 16,102 shares, decreasing direct ownership by 3% to 466,686 units (SEC Form 4)

    4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

    9/19/25 5:30:46 PM ET
    $OBIO
    Medicinal Chemicals and Botanical Products
    Health Care

    $MDT
    $OBIO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Medtronic BrainSense™ Adaptive Deep Brain Stimulation named a 2025 TIME Best Inventions

    TIME Best Inventions honors extraordinary innovations changing lives DUBLIN, Oct. 9, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that BrainSense™ Adaptive Deep Brain Stimulation (aDBS) – the world's first closed-loop DBS system for people with Parkinson's – has been recognized by TIME on its annual list of Best Inventions. There are over 10 million people living with Parkinson's disease globally,1 and while there is currently no cure, Medtronic deep brain stimulation (DBS) has been transforming the lives of people with Parkinson's and other neurological disorders for more than 30 years. Medtronic recently enhanced its Percept™ DBS

    10/9/25 10:10:00 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Orchestra BioMed to Showcase Transformative Potential of AVIM Therapy in Keynote Presentation on Hypertensive Heart Disease at Georgia Innovation Summit

    Presentation to provide comprehensive overview of AVIM Therapy clinical evidence demonstrating the potential to halt the progression of hypertensive heart diseaseOrchestra BioMed and Medtronic (NYSE:MDT) have a strategic collaboration to develop and commercialize AVIM Therapy for the treatment of uncontrolled hypertension in patients indicated for a pacemaker, an estimated global population of over 750,000 patients annuallyAVIM Therapy has received FDA Breakthrough Device Designation for the treatment of uncontrolled hypertension in patients with increased cardiovascular risk, an estimated U.S. population of over 7.7 million patients NEW HOPE, Pa., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Orches

    10/9/25 8:00:00 AM ET
    $MDT
    $OBIO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Medicinal Chemicals and Botanical Products

    Medtronic initiates U.S. IDE clinical study evaluating Hugo™ robotic-assisted surgery system for gynecological procedures

    First procedures completed and enrollment underway in Embrace Gynecology study, furthering the company's progress to expand minimally invasive treatment options to patients in the United States GALWAY, Ireland, Oct. 8, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT) today announced the start of the Embrace Gynecology investigational device exemption (IDE) U.S. clinical study to evaluate the safety and effectiveness of its Hugo™ robotic-assisted surgery (RAS) system in robotic-assisted gynecological procedures. The first procedures, total hysterectomies, were successfully completed at AHN West Penn Hospital in Pittsburgh, PA, by Dr. Sarah Crafton and Dr. Eirwen Miller, Embrace Gynecology study

    10/8/25 7:00:00 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MDT
    $OBIO
    SEC Filings

    View All

    SEC Form 25-NSE filed by Medtronic plc.

    25-NSE - Medtronic plc (0001613103) (Subject)

    9/29/25 10:44:27 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form CERT filed by Medtronic plc.

    CERT - Medtronic plc (0001613103) (Filer)

    9/29/25 9:53:17 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 8-K filed by Medtronic plc.

    8-K - Medtronic plc (0001613103) (Filer)

    9/29/25 8:45:28 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MDT
    $OBIO
    Leadership Updates

    Live Leadership Updates

    View All

    Medtronic announces appointment of MiniMed chief financial officer ahead of intended separation into standalone company

    GALWAY, Ireland, July 8, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced the appointment of Chad Spooner as chief financial officer (CFO) of MiniMed, in advance of its intended separation into a standalone, public company. Effective July 14, 2025, Chad will be responsible for overseeing the Finance function for Medtronic Diabetes and supporting initiatives aimed at accelerating profitable growth and delivering shareholder value as it prepares to become fully independent.  Chad brings over 25 years of financial leadership experience across healthcare, consumer, and industrial sectors. Most recently, he served as CFO at BIC (BB:PA), a pu

    7/8/25 8:45:00 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Medtronic Board appoints Dr. Joon Lee as a new director

    GALWAY, Ireland, June 23, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that its Board of Directors appointed Dr. Joon Lee, CEO at Emory Healthcare, Inc., to the Board as an independent director, effective June 18, 2025. Dr. Lee will serve on the Science and Technology Committee and Compensation and Talent Committee of the Board. "We are thrilled to welcome Dr. Lee, a highly respected interventional cardiologist and healthcare executive, to Medtronic's Board of Directors," said Geoff Martha, chairman and chief executive officer. "Dr. Lee brings deep expertise as a clinical researcher, academic leader, and physician executive with dec

    6/23/25 4:15:00 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Orchestra BioMed Reports Full Year 2024 Financial Results and Provides a Fourth Quarter Business Update

    NEW HOPE, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company")), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its full year 2024 financial results and provided a fourth quarter business update. "We remain highly focused on execution of the BACKBEAT global pivotal study, which we believe has the potential to deliver landmark results that can establish AVIM therapy as a new standard of care for the treatment of uncontrolled hypertension in patients already indicated for a pacemaker. We also believe it can lay the foundation for

    3/31/25 4:21:30 PM ET
    $MDT
    $OBIO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Medicinal Chemicals and Botanical Products

    $MDT
    $OBIO
    Financials

    Live finance-specific insights

    View All

    Medtronic reports first quarter fiscal 2026 financial results

    11th quarter in a row of mid-single digit organic revenue growth;Poised to accelerate growth GALWAY, Ireland, Aug. 19, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced financial results for its first quarter (Q1) of fiscal year 2026 (FY26), which ended July 25, 2025. Key Highlights Revenue of $8.6 billion, adjusted revenue of $8.5 billion, increased 8.4% as reported and 4.8% organicGAAP diluted EPS of $0.81 increased 1%; non-GAAP diluted EPS of $1.26 increased 2%Company raises FY26 EPS guidance; reiterates FY26 organic revenue growth guidanceCardiac Ablation Solutions revenue increased nearly 50%, incl

    8/19/25 6:45:00 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Medtronic announces cash dividend for second quarter of fiscal year 2026

    GALWAY, Ireland, Aug. 14, 2025 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE:MDT) on Thursday, August 14, 2025, approved the company's cash dividend for the second quarter of fiscal year 2026 of $0.71 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in May 2025. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 48 consecutive years. The dividend is payable on October 17, 2025, to shareholders of record at the close of business on September 26, 2025. About Medtronic Bold thinking. Bolder actions. We are Medtronic. Medtronic plc,

    8/14/25 4:15:00 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Medtronic announces cash dividend for fourth quarter of fiscal year 2025

    GALWAY, Ireland, March 6, 2025 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE:MDT) on Thursday, March 6, 2025, approved the company's cash dividend for the fourth quarter of fiscal year 2025 of $0.70 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in May 2024. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 47 consecutive years. The dividend is payable on April 11, 2025, to shareholders of record at the close of business on March 28, 2025. About MedtronicBold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquart

    3/6/25 4:30:00 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MDT
    $OBIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Orchestra BioMed Holdings Inc.

    SC 13D/A - Orchestra BioMed Holdings, Inc. (0001814114) (Subject)

    8/7/24 5:19:57 PM ET
    $OBIO
    Medicinal Chemicals and Botanical Products
    Health Care

    Amendment: SEC Form SC 13D/A filed by Orchestra BioMed Holdings Inc.

    SC 13D/A - Orchestra BioMed Holdings, Inc. (0001814114) (Subject)

    8/7/24 5:16:55 PM ET
    $OBIO
    Medicinal Chemicals and Botanical Products
    Health Care

    Amendment: SEC Form SC 13G/A filed by Orchestra BioMed Holdings Inc.

    SC 13G/A - Orchestra BioMed Holdings, Inc. (0001814114) (Subject)

    7/17/24 4:32:50 PM ET
    $OBIO
    Medicinal Chemicals and Botanical Products
    Health Care